The Empowering Voices: Knowledge and Decision-Making Among People Impacted by Lung Cancer in Europe report, conducted by Lung Cancer Europe (LuCE) with the support of 40 member organisations, features ...

NCoR1/RARα interaction was identified as a target for selective chaperone-mediated autophagy (CMA) inhibition in lung cancer.

While smoking is the leading cause of lung cancer it is not the only cause In fact many people develop lung cancer despite ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

The lung cancer diagnostics market encompasses tools, techniques, and services for detecting lung cancer, including imaging, ...

“Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what’s possible for patients with ROS1-positive non-small cell lung cancer ...

Zidesamtinib is currently being evaluated in the ongoing ARROS-1 Phase 1/2 trial for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors, which is ...

NEW YORK, February 03, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has ...

Approval is based on the pivotal Phase 2 TRUST-I study, demonstrating taletrectinib's durable responses and prolonged progression-free survival NEW YORK, January 06, 2025--(BUSINESS WIRE ...